LDS/Medical Tests/Lysosomal Storage Disease Gene Mutation Panel, NGS

Lysosomal Storage Disease Gene Mutation Panel, NGS

Lysosomal storage diseases (LSD) are a heterogeneous group of inherited disorders involving the disruption of normal lysosome function. They are characterized by the accumulation of undigested glycosaminoglycans, glycoproteins and/or glycolipids within lysosomes. Disease results from progressive accumulation of these materials within cells, cellular damage, and tissue dysfunction. LSDs are typically inherited in an autosomal recessive manner with the exception of mucopolysaccharidosis type II (MPS II) also known as Hunter syndrome, Danon disease, and Fabry disease, which all demonstrate X-linked inheritance.

LSDs comprise more than 50 metabolic disorders including defects in degradative and synthetic enzymes, lysosomal membrane defects, neuronal ceroid lipofuscinoses (NCLs) and disorders of lysosome biogenesis and endosome–lysosome traffic. Disease manifestations depend on the specific accumulated substrate, the site of production and degradation of the substrate and amount of residual enzyme activity, but in general, LSDs are characterized by a progressive course with high morbidity and mortality and a decreased lifespan. LSDs are multisystemic disorders and may present as infantile, juvenile, or adult onset forms. All forms are characterized by both peripheral and central nervous system symptoms. Additional clinical features include coarse facial features, organomegaly, visual disturbances, cherry red spot observed on ophthalmologic exam, corneal clouding, hearing loss, white matter abnormalities, central nervous system dysfunction, developmental regression, skeletal dysplasia, contractures, short stature, hepatosplenomegaly, acroparaesthesias, interstitial lung disease, cytopenias, angiokeratomas, movement disorders, leukodystrophy, cardiomyopathy, psychiatric features and renal failure.

The overall incidence of LSDs as a group is estimated to be 1 in 5,000 births. LSDs are caused by pathogenic variants genes resulting in a deficiency of enzyme activity or protein function. However, LSDs share one common biochemical characteristic: an accumulation of substrates within lysosomes. The particular substrates that are stored and the sites of storage vary. The substrate type is used to group the LSDs into broad categories, including mucopolysaccharidosis, lipidoses, glycogenoses, oligosaccharidoses, and NCLs. Despite this categorization, many clinical similarities are observed between groups as well as within each group. Molecular tests are helpful for the confirmation of the diseases.

Panel Components:

Although it depends on the laboratory and the clinical utility this panel uses targeted next-generation sequencing to evaluate for most common variants within genes: AGA, AP3B1, ARSA, ARSB, ASAH1, CLN6, CLN8, CTNS, CTSA, CTSK, FUCA1, GAA, GALC, GALNS, GBA, GLA, GLB1, GM2A, GNPTAB, GNPTG, GNS, GUSB, HEXA, HEXB, HGSNAT, HYAL1, IDS, IDUA, LAMP2, LIPA, LYST, MAN2B1, MANBA, MCOLN1, MLPH, MYO5A, NAGA, NAGLU, NEU1, NPC1, NPC2, NPR2, PPT1, PSAP, RAB27A, SGSH, SLC17A5, SMPD1, SUMF1, TPP1.

  • Diagnostic confirmation of lysosomal storage disease
  • To differentiate the different groups of lysosomal storage disorders
  • For the carrier testing in family members of the affected patient
  • Prenatal screening in at-risk pregnancies
  • Helpful for the prognosis and future therapeutic intervention

Positive

  • At least one known pathogenic variant or mutation associated with lysosomal storage disorder should be detected in the tested genes. Pathogenic variants may include small intragenic deletions/insertions and missense, nonsense, and splice site variants.

Negative

  • No mutation or pathogenic variant in the tested genes.

Negative for mutations or pathogenic variants in the tested genes

Next-Generation (NGS)/Massively parallel sequencing (MPS), conventional Sanger sequencing.

Whole blood (EDTA).

Stability

  • Ambient: 3-5 days
  • Refrigerated: 7-14 days
  • Frozen: Unacceptable
α-Gal A enzyme analysis, Lyso Gb3 biomarker analysis, deletion/duplication analysis, Urinary glycosaminoglycan (GAG) - Dermatan sulfate, heparan sulfate, iduronate 2-sulfatase enzyme activity, mucopolysaccharidosis II (MPS II) test, comprehensive mucopolysaccharidosis (MPS) panel, α-L-iduronidase (IDUA) enzyme activity, N-sulphoglucosamine sulphohydrolase enzyme assay, Mucopolysaccharidosis Type III (MPS III) Panel.
2-3 weeks.
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login